QLESP Block for Pain Control in Robotic Partial Nephrectomy

Sponsor
Huazhong University of Science and Technology
Study ID
NCT07704970
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Nerve Block
  • Postoperative Pain
  • Renal Cell Carcinoma (Kidney Cancer)

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • ropivacaine (local infiltration) — DRUG
    Ultrasound-guided QLESP block with 30 mL of 0.375% ropivacaine (15 mL injected between the erector spinae muscle and the transverse process at L2 level, followed by 15 mL injected between the quadratus lumborum and psoas major muscles) after induction of general anesthesia.
  • ropivacaine — DRUG
    Local wound infiltration with 30 mL of 0.375% ropivacaine at the port sites performed by the surgeon at the end of surgery.

Study Details

The goal of this clinical trial is to learn if an ultrasound-guided nerve block called QLESP works to reduce pain and the need for strong pain medicines after robotic kidney surgery in adults. The main questions it aims to answer are: 1. Does QLESP reduce the total amount of opioid pain medicine participants need in the first 48 hours after surgery? 2. Does QLESP lower pain scores and improve recovery quality after surgery? Researchers will compare participants who receive QLESP block to participants who receive the same numbing medicine injected only at the surgical wound sites. Participants will: 1. Be randomly assigned to receive either QLESP or local wound injection before surgery. 2. Have a patient-controlled pain pump for 48 hours after surgery. 3. Complete pain scores and recovery quality questionnaires at 2, 6, 12, 24, 48, and 72 hours after surgery. 4. Be followed until hospital discharge.

Key Dates

First listed
Jul 15, 2026
Start date
Jul 20, 2026
Status verified
Jul 2026
Primary completion
Feb 28, 2027
Completion
Mar 31, 2027

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: QLESP Group
    Participants receive ultrasound-guided QLESP block with 30 mL of 0.375% ropivacaine (15 mL in the erector spinae fascial plane and 15 mL in the quadratus lumborum-psoas major interfascial plane) after induction of general anesthesia.
  • Active Comparator: Control Group
    Participants receive local wound infiltration with 30 mL of 0.375% ropivacaine at the port sites performed by the surgeon at the end of surgery.

Primary Outcome Measure

Cumulative Opioid Consumption at 48 Hours Postoperatively [ Time Frame: From the end of surgery to 48 hours postoperatively. ]

Central Contacts

Related Studies